ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancer

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024Подробнее

ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBCПодробнее

Expert Report on novel data in (neo)adjuvant treatment of melanoma from ASCO 2022Подробнее

ESMO Daily Reporter Talk: The role of CDK4/6 inhibitors in the early stage of #breastcancer.Подробнее

Key Takeaways from ESMO: CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast CancerПодробнее

Breast cancer at ESMO 2020: CDK4/6 inhibitors and checkpoint inhibitorsПодробнее

ESMO 2020 Expert Video Report on 1st line ICI for gastro oesophageal cancerПодробнее

Expert video report on Urothelial Carcinoma from 2021 Genitourinary Cancers SymposiumПодробнее

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancerПодробнее

ESMO 2020 Highlights on adjuvant osimertinib for EGFR mutated NSCLC: The ADAURA studyПодробнее

Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast CancerПодробнее

ESMO 2020 Expert Video Report on precision medicine in prostate cancerПодробнее

ESMO 2020 Expert Video Report on studying further advanced ovarian cancerПодробнее

ESMO 2020 Expert Video Report on long term ICI outcomes in lung cancerПодробнее

Expert Commentary: Melanoma, Breast and Gynaecological Cancers at ESMO Congress 2021Подробнее

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancerПодробнее